Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30.06.2026.

DECIPHER Regd.Off: A-2, Q2, 5th Floor, Cyber Towers, Hitech City, Madhapur, Hyderabad, Shaikpet, Telangana, India, 500081 L ABS L IMITE D Ph: (+91)-40-48536100 Url: www.decipherlabs.in Mail: decipherlabsltd@gmail.com Formerly Combat Drugs Limited D.L. No. TG/15/04/2016-14766/14767 CINNo.L24230TG1986PLC006781 GST:36AAACC8372L1ZB Date: 13.08.2026 BSE Limited P. J. Towers, Dalal Street, Mumbai – 400001 Dear Sir/ Madam, Unit: Decipher Labs Limited (Scrip Code: 524752) Sub: Outcome of Board Meeting held on 13.08.2026 With reference to the subject cited, this is to inform the Exchange that the Board of Directors of Decipher Labs Limited at its meeting held on Thursday, the 13th day of August, 2026 at 02:30 p.m. at registered office of the Company for the quarter ended 30th June, 2026 considered and approved the following: 1. Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026. (Attached) 2. Limited Review Report (Standalone and Consolidated) for the quarter ended 30th June, 2026. (Attached) 3. Appointment of Mr. Bhupendralal Waghray (DIN - 07337149) as an Additional Director (Independent Category) of the Company for a period of Five (5) years w.e.f. 13.08.2026, subject to approval of members in the ensuing General Meeting. (Details are annexed as Attached A) The meeting concluded at 04:30 P.M. This is for the information and records of the Exchange, please. Thanking you. Yours Faithfully For Decipher Labs Limited Dalavath Amarsingh Whole Time Director (DIN: 02206249) DECIPHER Regd.Off: A-2, Q2, 5th Floor, Cyber Towers, Hitech City, Madhapur, Hyderabad, Shaikpet, Telangana, India, 500081 L ABS L IMITE D Ph: (+91)-40-48536100 Url: www.decipherlabs.in Mail: decipherlabsltd@gmail.com Formerly Combat Drugs Limited D.L. No. TG/15/04/2016-14766/14767 CINNo.L24230TG1986PLC006781 GST:36AAACC8372L1ZB Annexure – A [Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular SEBI/HO/CFD/PoD-2/P/CIR/2026/1 dated January 30, 2026)] Particulars Mr. Bhupendralal Waghray 1. Reason for change viz. Appointment of Mr. Bhupendralal Waghray as an appointment, Additional Director (Independent Category) of Decipher resignation, removal, death or Labs Limited. otherwise 2. Date of Appointment/ cessation Date of Appointment: 13.08.2026 applicable) & term of Terms of Appointment: Appointed for the period of Five Appointment (5) year(s), subject to the approval of shareholders. 3. Brief profile (in case of A seasoned government officer with 38 years of service in appointment) the Commercial Tax Department, Government of Andhra Pradesh, having served as a Deputy Commercial Tax Officer with extensive experience in tax administration and revenue matters. 4. Disclosure of relationships Not Applicable between directors (in case of appointment of a director) 5. Information as required Mr. Bhupendralal Waghray is not debarred from holding pursuant to BSE Circular with office of Director by virtue of any Securities and ref. no. LIST/COMP/14/2018- Exchange Board of India (SEBI) order or any other such 19 and the National Stock statutory authority. Exchange of India Ltd with ref. no NSE/CML/2018/24 dated June 20, 2018 DECIPHER LABS LIMITED. (CIN L24230TG1986PLC006781) Regd.off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081 URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040 29323151 Statement of Unaudited Standalone Financial Results For the Quarter Ended 30th June, 2026 All amounts in ₹ Lakhs, unless otherwise stated Particulars Quarter ended Year ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Unaudited Audited Unaudited Audited I. Revenue from operations 9.81 6.69 84.65 113.54 II. Other income - 0.11 - 0.13 III.Total Income (I + II) 9.81 6.80 84.65 113.67 IV. Expenses Purchase of Stock in trade - 0.40 64.10 64.50 Changes in inventories of finished goods 0.40 (0.40) - (0.40) Employee Benefits Expense 5.49 5.32 3.85 17.53 Depreciation expense 0.45 0.45 0.45 1.80 Other expenses 11.35 18.39 10.22 54.08 Total expenses 17.69 24.15 78.62 137.51 V. Profit/(Loss) before Exceptional items (III - IV) (7.88) (17.35) 6.03 (23.84) VI. Exceptional items - - - - VII. Profit/(Loss) after Exceptional items (V - VI) (7.88) (17.35) 6.03 (23.84) VIII. Tax expense: (1) Current tax - - - - (2) Deferred tax 0.04 (0.04) 0.44 0.85 IX. Profit/(Loss) for the period (VII-VIII) (7.93) (17.31) 5.59 (24.68) X. Other comprehensive income - - - - XI. Total comprehensive income for the year (7.93) (17.31) 5.59 (24.68) Paid Up Equity Share Capital (FV of Rs 10 each) 1,010.00 1,010.00 1,010.00 1,010.00 XII. Earning per equity share (1) Basic (0.08) (0.17) 0.06 (0.24) (2) Diluted (0.08) (0.17) 0.06 (0.24) Notes 1. The operations of the Company relate to two segments viz:, Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services. Segment Information: Particulars Quarter ended Year Ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Unaudited Unaudited Unaudited Audited Segment Revenue a) Manufacturing and Trading of Pharmaceutical drugs 0.40 - 67.50 67.50 b) Consultancy Services 9.41 6.69 17.15 46.04 Total Sales 9.81 6.69 84.65 113.54 Less: Inter Segment Revenue - - - Total Revenue from Operations 9.81 6.69 84.65 113.54 Segment Result (Profit Before Tax and Interest from each Segment) a) Manufacturing and Trading of Pharmaceutical drugs (0.32) (10.07) 4.81 (14.17) b) Consultancy Services (7.56) (7.28) 1.22 (9.66) Total (7.88) (17.35) 6.03 (23.83) Less: Interest and exceptional items - - - - Total Profit before tax (7.88) (17.35) 6.03 (23.83) Capital employed (Segment assets - segment liabilities) Segment assets a) Manufacturing and trading of Pharmaceutical drugs 902.14 899.52 999.00 899.23 b) Consultancy Services 5.20 - 4.28 - Total Assets 907.34 899.52 1,003.28 899.23 Segment liabilities a) Manufacturing and trading of Pharmaceutical drugs 91.21 75.47 148.96 75.47 b) Consultancy Services - - - - c) Unallocated liabilities - - - - Total Liabilities 91.21 75.47 148.96 75.47 2.Theaboveresultsforthequarterended30thJune2026werereviewedbytheAuditCommitteeandapprovedbytheBoardofDirectors of the Company at their meeting held on 13th Aug 2026. 3.ThefinancialresultsoftheCompanyhavebeenpreparedinaccordancewithIndASprescribedunderSection133oftheCompanies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure 4. The Government of India has notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the “New Labour Codes”) - consolidating 29 existing labour laws. The New Labour Codes are effective from November 21, 2025. The Company has estimated no liability for own employees and is in the process of evaluating other possible impacts including for contract workforce. For and on behalf of the Board Amar Singh Dalavath Place: Hyderabad Whole Time Director Date: 13.08.2026 DIN: 02206249 DECIPHER LABS LIMITED. (CIN L24230TG1986PLC006781) Regd.off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081 URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040 29323151 Statement of Unaudited Consolidated Financial Results For the Quarter Ended June 30, 2026 All amounts in ₹ Lakhs, unless otherwise stated Quarter Ended Year Ended Particulars 30.06.2026 31.03.2026 30.06.2025 31st March, 2026 Unaudited Unaudited Unaudited Audited I. Revenue from operations 241.39 360.40 292.37 1,405.40 II. Other income 9.75 17.37 1.12 22.09 III.Total revenue (I + II) 251.13 377.77 293.49 1,427.49 IV. Expenses Purchase of Stock-in-Trade - 0.40 64.10 64.50 Changes in inventories of finished goods 0.40 (0.40) - (0.40) Employee benefits expense 275.96 267.82 472.61 1,498.67 D [Showing first 8,000 characters — download PDF for full document]